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Reduction in frequency or severity of side etTects associated 
with medical practices not only may improve patient out- 
come, but also may atfect patient care wsts. Studies suggest 
that low osmolality radiographic ontrast medium may cause 
fewer adverse drug reactions than high osmolality conhast 
medium when used in diagnostic angiocardiography (I-14). 
Because low osmolality contrast medium is priced 10 to 
20 times higher than hi osmdality contrast medium, 
physicians and hospitals have been cotxemed that a con~cr~ 
sion from a high to a low osmolality agent would substan- 
tially increase costs of omvidiw care (15.16). In diw,nostic 
angiocardiognphy, thedifference in price between the two 
media ranges from $136 to $187 for a single procedure 
(17-19). In our hospital, where =l.SlX diagttortic angiow- 
diographic pmcedorrs are performed each year, total sub- 
stitution of a low osmolality for a high osmolality agent in 
these procedures would require an additional ottday of 
$204@0 to $28O,Molyear. In the United States, where =I 
million diagnostic angiwardiogmphic procedures (20) are 
performed each year by 1.300 health care institutions (21). 
use of a low osmolality wsos a high osmolality .ageigent in 
diagnostic angiocardiography would add $136 to $187 million 
to annual health care expenditures. Thus, low osmolality 
contrast medium is representative of expensive “little- 
ticket” pharmaceuticals (i.e., those whose price is relatively 
small for a single prescription but whose volume of use is 
high enough to result in large aggregate costs). 
We rewrt au analysis of the costs associated with man- 
aging ad&se drug reactions and the resulting net costs 
associated with use of low osmolalitv versus hinh osmolality 
contrast medium (i.e., the extent to which the higher price if 
low osmolality agents is offset by savings associated with 
managing fewer or less severe adverse drug reactions with 
such agents than with high osmolality agents). The analysis 
was performed from three perspectives (that of the hospital, 
a third-party payer and society), with the intent to guide 
hospital decision-making with regard to the use of low 
osmolality versus high osmolality contrast medium and to 
assist public and private insurers in formulaling payment 
policies for low osmolality agents. 
Methods 
Study design. We conducted our economic evaluation in 
conjunction with a randomized, double-blind trial of 505 
patients undergoing diagnostic angiocardiography (coronary 
arteriography with or without ventticulography) between 
April 1989 and December 1990, with either diatrizoate 
meglumine-sodium (Hypaque 76) or iohexol (Omnipaque 
350). Patient eliibility criteria, techniques of diagnostic 
an&cardiography, randomization and measurement of clin- 
ical outcomes have been reported elsewhere (22). Of the 
eligible population, 40% was enrolled: 100% of enrolled 
patients were followed up for at least 24 h and 53% for at 
least 48 h. Eligible oatients were not enrolled owina to lack 
ofpatient con&t (53%). lack of referring physicianconsent 
(l3R, judgment by the cardiology fellow that the patient 
was at high risk (a%), administrative error (1%) and mis- 
cellaneous reasnns (7%) (22). Adverse drug reactions in- 
cluded I) cardiovascular events, 2) “allerav-like” events 
(e.g., hives, itching), 3) thrombaembolic events (coronary, 
cerebral or peripheral arteries), 4) other events (e.g., nausea, 
vomiting), and S) nephmtoxicity. Without knowledge of the 
contrast medium used, we used exolicit criteria to classify 
adverse drug ,eactions into one of four severity levels (I 4 
minor: 4 = maior) (see Avoendix). The Institutional Review 
Board approvid ;he studyon January 10, 1989. 
Measurement of waurn use. Figure 1 shows an over- 
view of the process used to estimate the cost of managing 
adverse drug reactions from various perspectives. The first 
step was to meawe incremental resources used during a 
patient’s hospital stay to manage an adverse drug reaction 
(i.e., resources that would not have been used in the absence 
of such a reaction). Resources examined included extra time 
spent in the catheter pmcedure room, laboratory tests. 
radiology procedures, medications, other diagnostic and 
therapeutic services, additional hospital days, consultations 
and physician care for additional days. 
A research uurse observed the procedure and used stau- 
dardized forms to record the number of contrast medium 
bottles opened and amount administered, occurrences of 
adverse drug reactions and all resources used to manage 
them. The amount of time consumed in managing an adverse 
drug reaction was estimated by review of a time log. The 
nurse visited the inpatient unit daily for up to 48 h after 
angiogtaphy, or until hospital discharge if the discharge 
occurred earlier, to ascertain by chart review whether pa- 
tients experienced additional adverse drug reaetions and 
whether additional resources were consumed. Patients who 
expwienced an adverse drug reaction were followed up daily 
until it resolved or the patient died or was discharged. Alter 
reviewing the medical record, the nursa tabulated re~ourcea 
that wei Eonsumed and po!en!ially Mated to an adverse 
drug reaction. Tile patielt’s physicians were interviewed 
using a standardized protocol to deteradm which resouree 
use was incremental (i.e., would not have been consumed in 
the absence of the adverse drug reaction). 
Mcuuremen~ of Eosla. We identikd costs of resources 
urexl during a @ent’s hospitalization to manage adverse 
drug reactions fmm the prspective of society, the hospital 
and a third-party payer. Average and differential cost8 to the 
hospital and charges to the third-party payer for hospital 
services and pmfessioual fees were identilkd by evaluation 
of expenditure records corresponding to the actual period in 
which resources were consumed. 
IdentitkaUon af average eosk Average costs are defined 
as the total costs of producing the tatal number of units of a 
specific resource (without cokideration of clinical applica- 
tion) divided by the total number of units produced (23). For 
example, if the total (fixed and variable) annual costs lo 
perform 100,000 chemistry panels in the laboratory is 
SSC4,oW, then the average cost of a chemistry panel is IS. 
Historically. long-nm average costs have been ured to 
establish payment rates and are often used to estimate 
long-run production costs to society for hospital services. 
Average cost for additional time spent in the catheteriza- 
tion suite was defined as the total annual costs associated 
with space and labor for ?iz+gmxtic zgiocardiogrzphy di- 
vided by the annual sum of the duration of all procedures. 
Cost of drugs was defined as the sum of the acquiritior :os!. 
the cost of pharmacy preparation (calculated using industrial 
engineering standards) and the cost of supplies required to 
administer the drug. 
Resources consumed on inpatient units (e.g., laboratory 
tests) were assigned costs using the ratio of costs to charges 
for each hospital revenue center. The revenue center level is 
service spccilic. For example, the costs of oxygen adminis- 
tration and serum creatinine derermination are derived from 
separate ratios because they an provided by different cen- 
ters. Revettue center costs include direct operating costs 
(labor, materials, supplies) and allocated overhead (e.g., 
hos&l debt service, hasoital administrative costs). The 
cosi of mom and board was assigned using sbmdard cost- 
accounting procedures. Costs for a day when a patient’s unit 
was changed fmm routine to cardiac care were cal,:ulated by 
subtracting the mutine unit cost t?om the cardiac czre unit 
cost. Total average costs were defined as the sum of costs of 
time. drugs, ancillary services and rwtn and board. 
IdenS of dilfewdjal c&s. Differential costs, the 
mast accurate reflection of costs that hospitals incur in 
managing contrast medium-related adverse drug reactions, 
are incremental costs of producing additional units of service 
associated with use of one clinical strategy versus an alter- 
aative strategy (24). For example, suppose that the strategy 
of using high osmolality contrast medium is chosen over a 
strategy of using low osmdality contrast medium and that 
this results in an annual increase of 100 chest radiographs 
perforated as pari of the management of adverse drug 
reactions. The cost for performance of these chest radio- 
graphs is variable with respect to supplies used (o.g., extra 
X-ray film is required), but it may not be variable with 
respect to labor input (e.g., no extra radiology technologist 
may bs required). Diierential costs we similar but no! 
identical to marghml costs in that marginal cost is the 
incremental cost incurred to provide only one additional unit 
of service. LUierential cost is a better r&ction than mar- 
ginal cost of the actual iacremental cost experience if there 
are input casts (e.g., labor) that vary when a threshold 
volume is reached. 
To assign differential costs, we first estimated the ditfer- 
ewe in hospital resources use for I year associated with a 
strategy of alI patients receiving low osmolality contrast 
medium versus a strategy of all patients receiving high 
osmolality contrast medium, using resource use data on the 
emulkd patient gmup to model the volume of use of each 
rewt-ee far ail clinically similar patients undergoing diag- 
nostie aagiocardiography. We then estimated the incremen- 
tal cost of pmvidiag the diierence in resources through 
structured interviews with department administrators. For 
f:ach resource provided by a cost center. we supplied the 
relevant administratorwith theexpecteddiiereea inaoooal 
use between strar:gics of using high osmolaiity versus low 
osmolality con!ra.t medium in all patients. We then asked I) 
What types of costs (labor, capital. su~diisl would cbwx 
with v&!tons in service voiumes e&d to the expected 
Mere ace I resource use between the two clinical strate- 
@es? 2) What would be the change in costs if the volume 
were changed by this magnitude? The answer to these 
questions, in combination with cost center accounting&to, 
allowed us to calculate the diffwential cost per patient 
associated vith the observed incremental volume of re- 
sources. 
~detttiE+xtion f char@s aad pmfessioopl feg. Charges 
and professional fees that providers attach to incremental 
resources (less discounts) are th ios:s <hat insurers bear in 
the absence of risk bearing by providers. Cost to payers for 
resources consumed on inpatient units. including ancillary 
services and additional days of care, were the actual charges 
for these resources (abstracted from patient biis) less dis- 
counts for select large volume payers. In Maryland. art 
all-payer rote-setting state, charges minus small discounts 
are the actual costs faced by payers. Cost of inpatient unit 
drugs was csthnated by applying the pharmacy cost/charge 
ratio to the drug costs. Physician care costs to payers were 
determined by using a fee profile of actual physician pay- 
ldenti6calioo d cmt d cr.dms~ 
media was taken to be the acattisition cost (price minus 
discounts) of bottles that were opened for us; duriag the 
diagnostic angiocardiogtaphii procedure. 
StatisticA wdysi?. We calctdsted point estimates and 
95% confidence intervals for frequency of adverse drug 
reactions with high osmoialily and low osmolality contrast 
medium and for the relative risk of an adverse drug reaction 
of any type, and each of the four severity levels. with low 
osmolality compared with high osmolality contrast medium. 
We used aonpacttmetric statistics (Wdcoxon rank sum test) 
to compare the observed costs of managing adverse drug 
rewtions I) across all patients who received hi osm&dity 
versus those who received low osmolality contrast medium, 
and 2) associated with severity level-specific adverse drug 
reactions in the two cordmst medium groups. Observed 
costs of severity level-specific adverse drug reactions also 
were log transformed, and diierenees between the two 
contrast medium groups were compared (t test). 
In a srxitivity analysis, we examined the difference in 
expected per patient cost of managing advene drug reac- 
[ions with high osmolality versus low osmolality contmst 
medium as a function of variability in 1) the di&ence in 
mean costs of severity level 4 (severe) adverse drug reac- 
tions for the two media: 2) the relative risk of a level 4 
adverse drug reaction with the two media, and 3) the 
frequency of level 4 reactions with high osmolality contrast 
medium. In these sensitivity analyses, we used a Iwo-part 
model (part I = rate of adverse drug reaction; part 2 = cost 
peer adverse drug reaction) (25) to calculate the expected 
per patient cost of managing adverse drug reactions that 
occor~ with the two media. The overall expected cost of 
managing adverse drug reactions was the sum of the 
products of the adverse drug reaction rate and the mean 
cost of managing ao adverse drug reaction for each 
severity level. For adverse drug reaction costs, the mean 
was chosen as the measure of c&al tendency owing to the 
fact that a small number of individuals often account for a 
large proportion of the costs of health care (26). and these 
costs are important to health care managers and decision 
makers. 
Results 
Patient group and frequency of adverse drug reactions. 
Meat demograp!dc, clinical and payer (e.g.. Medicare) 
characteristics. including performance of ventriculography 
and use of wemedication, were similar for the 253 patients 
receiving high osmolality contrast medium (high os&lality 
group) and the 252 patients receivina low osmolalitv contrast 
medium (low osm&ality group). &cept for a higher fre- 
quency of digoxin use and prior renal disease (baseline 
creatinine ~1.5 me/dl) in the low ormolality group (22). 
Table 1 shows for both patient groups the overall adverse 
drug reaction experience and the severity level and relative 
risk of adverse drug reactions. The frequency of a mild (level 
21, moderate (level 3) and any reaction was lower (p < 
0.0001) in the low osmolality group. 
Cosls of adverse drug reacttins. Table 2 shows the fre- 
quency distributions of the costs of incremental resources 
used to manage adverse drug reactions. For both groups 
combined, TOom and board accounted for 40%. drugs 1%. 
laboratory services 5%. radiology services 4%, cardiae 
diagnostic services 4%. procedure loDm time 4% and mis- 
cellaneous services 23% of total average costs IO the hospi- 
tal. For both groups combined, room and board accoun<ed 
for 38%. professional fees 20%. dross 7%. labomtmv ser- 
vices h%,~mdiology services 4%; cardiac diagnostic services 
3%, procedure mom time 4% and miscellaneous services 
22% of payer costs. 
Although the distribution of payer costs was not sigtdfi- 
cantly different (p = 0.42, Wilcoxon) between the two 
groops. the distribution of average costs was siiihcantly 
different @ = O.COOl, Wilcoxon) in the high osmolality 
versus the low osmolality group. The major dbierenccs 
between the two distributions of average costs were a 
greater number of patients with zero average cost of man- 
aging adverse drug reactions in the low osmolality groop and 
Tabk 2. Frequency Distribution of Costs 
An LOCM 
In - so.9 ,n = 29, 
No.- No. % No. 46 
the existence of a high cost case (adverse drug reaction cost 
$39.057) in the high osmolality group. The mean average cost 
to the hospital of managing adverse drug reactions per 
patient undergoing diagnostic an&cardiography was $157 
hiilter in the hi& osmolality than in the low osmolality gmup 
(Table 3). This difference in mean avenge cost is driven by 
the highcostcase. lfthe patient whose adversedrugreaction 
generated average costs of $39,057 were deleted, for exam- 
ple, mean average costs in the high osmolality group would 
be $95 rather than $249 (p still < O.ooO1, Wilcoxon vs. low 
asmolality contrast medium). 
Because the mean material cost was $207 greater (p = 
O.OKll) for low osmolality than for high osmalality contrast 
medium, the savings in average cost to the hospital of 
managing adverse drug reactions when low osmolality ver- 
sus high osmolality contrast medium is used ($157) offsets 
75% of the difference in material cost for the two media. 
Similarly, savings in ditTerential costs of management of 
adverse drug reactions when low osmolality versus high 
osmolality contrast medium is used ($67) offsets 33% of the 
higher price of low osm&dity contrast medium. If the 
difference in observed mean payer costs for management of 
contrast-r&ted adverse drug reactions with low osmolality 
versus high osmdality contrast medium ($182) had bees 
statis!ically significant, the calculated &et would be 88% of 
the higher price of low osmolality contrast medium. 
Costs by adverse drq resctIatt zwzt+ly level. It is not 
surprising, as Table 4 shows, that the costs of managing an 
adverse drug reactiuu increase as its sevetity level increases. 
Comparison of the average cost to the hospital and payer 
costs within eachofthefoursevetity levelsshowedthatboth 
mean and median costs were higher for high osmolelity than 
for low osmolality contrast medium, but not signilicantly so 
(p > 0.05). However, the power to detect differences was 
limited. 
Sensitivity analyst Figure 2 shows that the diEerence in 
the expected average cost ffmm the two-pat model) of 
mans&g adverse drug reactions (levels I to 4) when low 
osmolality versus high osmolality contrast medium is Itsed 
increases as the reletive risk of a level 4 adverse drug 
reaction decreases over a plausible range (i.e., 95% conR- 
dence interval). When the observed costs of adverse drug 
reactions are used, the diierence in the average cost asso- 
ciated with management of adverse drug twctions fully 
offsets the difference in the material cost cf low osmolality 
versw Sigh ostnolality contrast medium end begins to make 
use of low osmolality contrast medium cost-saving when the 
relative risk of a level 4 adverse drug reaction is ~0.57. In 
contrast. when the pooled cost ofman;lgingalevel4adverse 
drug reaction is used for both contrast media, the cost offset 
related lo management dadverse drug reactions is substan- 
tially less at all relative risks, and use of low asmolality 
contmst medium never becomes cost saving. If the relative 
risk is 1.0. the o&t is i5%using pooled level4 adverse drug 
reaction costs. The rationale for the latter assumption (i.e., 
&RE) mst per patient undergo& diagnostic angiocardi&aphy 
ofmanaging adverse drug reactions IADRs) thatoecurin association 
with use of low osmolality (LOCM) versus high osmolality contrast 
medium (HOCMI to 1) the relative risk (LOCMXOCM) ofa severe 
(level 4) adverse dmg reaction, and 2) the cost associated with 
managing a were adverse dmareaction. Uwcr curve. DitTerenccin 
expected cost per patient of-nanaging an-adverse drug twaion 
when high osmolality rather than low osmolality contrast medium is 
used, assuming that the true mean cost of a were adverse drug 
reaction with high osmolality contwt medium is that observed in 
the trial (i.e., 112,425) and that the true mean cost of a severe 
adverse drug reaction with low osmolality cmttrast medium is that 
observed in the trial (i.e., $3,373). Lower wve. Difference in 
expected cost per patient of managing an adverse drug reaction 
when high asmolality rather than low osmolality contrast medium is 
used. assuming that the true mean cost of a severe adverse drug 
reaaionisthesamcregardlessoftypcofwntrastmcdium ured(i.e.. 
$6,994 = mean of pooled cost of the lo severe adverse drag 
reactions: 4 with high osmolality, 6 with low c+molality contrast 
medium). Open circle represents the observed point estmtatc in the 
clinical trial; the dwbed horizontal Ii*, shown for comwison, is the 
diiierence in mean material costs between low osmolality and high 
osmolality contrast medium. The low osmolality contrast medium is 
cost saving for any paint on a curve that lies above this line. 
for considering a “pooled cost” of $6,994 for managing a 
level 4 adverse drug reaction) is that there was no statisti- 
cally significant difference in the average cost of managing a 
level 4 adverse drug reaction in the low versus the high 
osnolality grow. 
Figure <sh&s that the higher the frequency of occur- 
rence of a level 4 adverse drug reaction with hiah osmolalitv 
contrast medium, the greater-the offset of thehifference in 
material costs that is due to costs associated with managing 
adverse drug reactions at any given relative risk for a level 4 
adverse drug reaction. With a level 4 adverse drug reaction 
rate for high osmolatity contrast medium of zero, the small 
o&et is due to differences between high osmolality and low 
osmoiality cootrast medium in levels I,2 and 3 adverse drug 
reaction rates and costs. 
Discussion 
Advances in medical science are making promising phar- 
macologic agents available for use in medical practice. Tbe 
prices of many of these new agents are high compared with 
Mawe 3. An&is of the sensitivitv of the difference in exacted 
(&rage) cost per patient undergoing diagnostic angi~ardi&aphy 
of managing adverse dlug reactions (ADR) that occur in association 
with use of low osmolality versus high osmolrdity contrast medium 
to I) the relative risk fLOCM:HOCM) ofa severe (level 41 adverse 
drugreaction. and 2) the rate of occurrence ofa severe adverse & 
reaction when hiah osmolalitv contrast medium is used. Uwcr curve 
when high osmdality contrast medium is wd is the upperiimit of the 
95% comidence interval (CD for ths rate of wcurrenw of a severe 
adveroedrugreactionobsmedinthehighoomdality~~con~dsfmediun: 
~~~oduringthirtrialli.e..0.031). InuercwcawmsthattheratecI 
&c&nceb were ad&se dw rexticms when high mmolality 
contrast medium is used isthe lower Omit oftbe93% Ctfartberateof 
occurrence of a severe adverse drw react& that was observed in the 
high asmdality gmup during this 11% (i.e.. 0). opll dr& represents 
the observed wint estimate in the clinical trial: the dmkd hwtzaM 
those of existing diagnostic and therapeutic agents, in part 
because of more complex production processes. royalties 
paid to patent owners and the desire of manufacturers to 
recover research and development costs andgenerate profits 
as quickly as possible. In light of intensified e&ts to 
restrain health care costs, hospitals and third-party payers 
must increasingly consider whether oew drugs are coot- 
effective (i.e., whether incremental benefits are worth the 
incremenlll costs). InfomKd decision-making &mot the use of 
new drugs will require comparative data, not only on clinical 
outcomes but also on net costs from dierent points of view. 
Our economic evaluation indicates that in diagnostic 
angiwardiography the fewer overall adverse drug reactions 
occurring with low osmolality versus high osmolality coo- 
trast medium are of mild and moderate severity and are 
relatively inexpensive to manage. Although we observed 
substantially greater expeaditures in management of severe 
adverse drug reactions among patients who received high 
osmolality contrast medium, the number of such adverse 
drag reactions that occurred was small and not statistically 
different in patients who received low osmolality versus high 
osmolality contrast medium. The costs of managing adverse 
drug reactions associated with use of contrast medium 
during diagnostic angioewdiography appear to be subs&a- 
tially greater than those associated with intravenous “ce 
(e.g., computed tomography or intravenous pyclography) 
(18,27,28). 
lmpliatiom for clintat sod payment pdiiies.Because of the 
diieriog perspectives of those who make policres affecting “se 
of low osmolality versus high osmolality comrast medium, we 
measured three types of costs. Diierentia! cost is the best 
estimate of the actual incren;sntal cost incurred by 3 hospital 
when implementing one patient management strategy versus 
an alternative strategy. Diereniial cost estimates. in coajunc- 
tion with diiTcrential resenoe estimates, are commonly used by 
hospital managers to decide whether spdic health programs 
are worth undertaking from a financial perspective. Our find- 
ings suggest hat the diierential hospital cost of incremental 
resources used to manage the greater number of adverse drug 
reactions that occurred in association with use of high “smo- 
lality contrast medium offset 33% of the greater matclial costs 
of the low osmolality medium. Thus. at least in diagnostic 
agiocardi”gmphy. the actual net cost of “ze of low osmolality 
rather than high osmolality contrast medium is less than the 
dilference between the ptices of the two types of media. The 
exact magnitude of the~diicrence is dticult to estimate pre- 
ciselv bwase of its sensitivitv to infresuent hi& cost cases. 
Be&se the o&et is only p.&tial, theie is sil a financial 
incentive for hospitals not to “se low osmoltity contrast 
medium in diagnostic aogiocardiagraphy because it increases 
net costs. and this higher cost may not be matched by an 
increase in revenue, particularly for hospitals reimbursed “D 
der per case o( prospective payment. Institutional consen~os 
must be reached with regard to whether the benefits of low 
osmolality contrast medium are worth this added cost. 
Incoarasttodiierential costs, avemge costs to the hospital 
provide an estimate of costs that society&l third-party p&s 
are likely to bear in the long run, whereas hospital charges plus 
txofessional fees constitute the costs faced by payers in the 
&t run. Our analysis suggests that in dia&stk angiocardi. 
ogtaphy, the higher average hospital costs of incremental 
resources used to manage adverse drug reactions assaiatcd 
with use of high osmolality rather than low osmolality contrast 
medium offsets 75% of the difference in material cost of the two 
agents. At “UT hospital this translates into a di5ereoce in “et 
total costs associated with use of low osmolality verws high 
osmolality contrast medium of $7WlWyear compared with a 
ditference of $3lO,_WUyear when only the price of contrast 
medium is considered. The difference in observed payer costs 
associated with adverse drug reaction mvlagement amounted 
to 88% of the dieerence in material costs of contrast medium 
but was not statistically sign&ant. 
hn@,,n ofawere reaiiom. Several aspects of our study 
should be hiited. First, fmm the three papectives. 
although almost all of the diierence in cost awxiatcd with 
alverse drug reaction management in the low osmolality com- 
pared with the high osmolality group was due to a ditTerence in 
the observed EN of managing sewe adverse drug reactions. 
we o&wed no statistically si&icant difference in either the 
rate of severe adverse drug reactions or the observed cost of 
sevem adverse &vg reactions in the two groups. Thus, al- 
though severe ~&use dmg reactiins occurring when low 
o:rnolality contrast media?! is used may actually be less 
expensive than those occtming when high osmolality cwllmrt 
medium is used. the cost otTsets that we calculated cmdd be 
due to statisncal variation in the costs aso&ted with the small 
number of severe odversedmg reactionsobserved inoorstudy 
rather than totlue differences insuchc”stsTbefact that mean 
average adverse dlug reaction C”ELE in tb hi osmolality 
group were sensitive to a high cost case illwrotes this point. 
However. our statistical power todetectadiiereoceinthec”+t 
of adverse drug reactions induced by low “sowtality velsos 
high osmolality contrast medium was low. 
We performed a sensitivity analysis to address uncer- 
tainty in both the relative risk and cost of severe adverse 
drug reactions. as well as the absolute frequency of “aor- 
rence of a severe adverse drug reaction with high osmolality 
contrast medium. This analysis demonstrates that the 
amount of the difference in material cost between the two 
media thal is otTset by the greater cost of managing more 
frequent adverse drug reactions with high osmolality versus 
low osmolality contrast medium is quite sensitive to I) the 
true relative nsk of severe adverse drug reactions with low 
osmolality verses high osmolality contrast medium, 2) the 
true difference in cost of managing severe adverse drug 
reactions that occur in conjunction with use of high “smo- 
lality versus low osmolality contrast medium. and 3) the 
abs&te risk of a severe adverse drug reaction when high 
osmolalitv contrast medium is used. Studies (18,29) have 
reported &es of severe adverse drug reactions as high as 
16% with high osmolality contrast medium, although the 
definition of severe adverse drug reactions in those studies is 
ditTerent from ours. 
Limitatiols cd the shdy. To some extent, our cost-benefit 
analvsis underestir=Les the actual material cost offsets that 
wooid be incurred iflow osmolality contrast medium wereused 
universally instead of high osmolality contrast medium. This is 
because patients who were thought likely to benefit the most 
from the iow wwk4ity mdh were exchtded born OUT 
study. and we did not include the cost of administering prc- 
medication that may reduce the incidence of adverse drug 
reactions when hii osmo!ality contrast medium is used. 
Moreover. we did not consider medicolegal or malpractice 
insurance costs that a hospital might incur in connection with 
the use of high osmo!ality verws low osmolality contmst 
medium. Our data would dither if we assumed I) that a 
moderate or severe adverse drug reaction would occur in 
13.4% more diagnostic ang’acardiogm9hy procedures at “UT 
institution when high osmo!Gty contrast medium is used 
(based on ““I trial twits): 2) that 0.79% OF patients with 
adverse events (not due to negligence) tile a malpractice claim 
(30): 3) that between 1979 and 1988 in Maryland, 21% of 
radiologists’ malpractice claims were closed and paid. and that 
the mean payment per closed claim was $202,062 in 1990 
dollars (31). Ontbisbasis, thcestimatcdotTset ofthediffereoce 
in mat&d costs between low osmolality and high osmolality 
contrast medium, taking into account the cost of both adverse 
dmg reaction management and malpractice claims versus tL 
cost of maoagawnt of adverse drag ractions alone. would be 
slightly greater both for the hospital (54% vs. 33%) and for 
society (98% vs. 75%). 
Furthermore, we examined costs associated with services 
provided during the hospital stay but not costs incurred by 
society or payers at&r hospital discharge. We also did not 
consider other costs relevant to society, such as indirect 
economic costs (e.g., income lost to patients or their fami- 
lies) or intangible costs (e.g., pain and suffering) related to 
adwrse drug reactions, or long-run costs relevant to an 
insurer’s perspective (i.e., resoorce~ used in the hospital to 
manage adverse drug reactions that are not billed in the short 
run but that migbt eventually be captured in provider’s 
charges to insurers in the long run). 
Our analysis also did oat include consideration of a 
strategy of administering low osmolality contrast medium 
only to patients at high risk and high osmolality contrast 
medium to all other patients. If such targeting is possible, 
overall costs would be reduced (22.32). 
Conclusl~. In summary, this study suggests that the 
higher material cost of use of low osmolality contrast me- 
dium in diagnostic angiocardiography is partially offset by a 
Appendix 
T&de Al. Criteria for Classifying Scveriw of Contrast Medium-Related Adverse Reactions* 
reduction in the cost of management of adverse drug reactions 
associated with low osmolatity wsus high osmolality conttast 
medium and that the magnitude of this offset varies with the 
perspective that is taken. More attention should be paid to net 
cab, from diierent perspctives, in consideration ofwhether 
expensive new technologies are cast-saving or cost-effective. 
